Acadia Pharmaceuticals (ACAD): Baker Bros. Advisors Buys More Shares

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

SCHEDULE 13D

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT

TO RULE 13d-l(a) AND AMENDMENTS THERETO
FILED PURSUANT

TO RULE 13d-2(a)

(Amendment No. 9)*

ACADIA Pharmaceuticals Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per
share

(Title of Class of Securities)

004225108

(CUSIP number)

Alexandra A. Toohey

Chief Financial Officer

Baker Bros. Advisors LP

667 Madison Avenue, 21^st Floor

New York, NY 10065

(212) 339-5690

(Name,
address and telephone number of person authorized to receive notices and communications)

August 9, 2016

(Date of event which requires filing of
this statement)

If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨.

(Continued on the following pages)

(Page 1 of 9 Pages)

________________________________

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP No.    004225108

Page   2   of   9   Pages

1.	NAMES OF REPORTING PERSONS Baker Bros. Advisors LP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*      (a) ¨                                                                                                                         (b) ¨
3.	SEC USE ONLY
4.	SOURCE OF FUNDS* OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)      ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER: 25,878,893 (1)
		8.	SHARED VOTING POWER: 0
		9.	SOLE DISPOSITIVE POWER: 25,878,893 (1)
		10.	SHARED DISPOSITIVE POWER: 0
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 25,878,893 (1)
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*      ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 21.6% (1)(2)
14.	TYPE OF REPORTING PERSON* IA, PN

(1)

Includes 3,125 shares of the common stock of Acadia Pharmaceuticals, Inc. (the “Issuer”) underlying options directly held by Julian C. Baker, a principal of Baker Bros. Advisors LP (“the Adviser”) and 56,000 shares of the common stock of the Issuer underlying options directly held by Dr. Stephen R. Biggar, an employee of the Adviser.

(2)

Based on 119,746,592 shares of the Issuer’s common stock outstanding as of August 10, 2016, as reported in the Issuer’s Prospectus filed with the Securities Exchange Comission (“SEC”) on August 10, 2016.

CUSIP No.    004225108

Page   3   of   9   Pages

1.	NAMES OF REPORTING PERSONS Baker Bros. Advisors (GP) LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*      (a) ¨                                                                                                                         (b) ¨
3.	SEC USE ONLY
4.	SOURCE OF FUNDS* OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)      ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER: 25,878,893 (1)
		8.	SHARED VOTING POWER: 0
		9.	SOLE DISPOSITIVE POWER: 25,878,893 (1)
		10.	SHARED DISPOSITIVE POWER: 0
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 25,878,893 (1)
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*      ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 21.6% (1)(2)
14.	TYPE OF REPORTING PERSON* HC, OO

(1)

Includes 3,125 shares of the common stock of the Issuer underlying options directly held by Julian C. Baker, a principal of the Adviser and 56,000 shares of the common stock of the Issuer underlying options directly held by Dr. Stephen R. Biggar, an employee of the Adviser.

(2)

Based on 119,746,592 shares of the Issuer’s common stock outstanding as of August 10, 2016, as reported in the Issuer’s Prospectus filed with the SEC on August 10, 2016.

CUSIP No.    004225108

Page   4   of   9   Pages

1.	NAMES OF REPORTING PERSONS Felix J. Baker
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*      (a) ¨                                                                                                                         (b) ¨
3.	SEC USE ONLY
4.	SOURCE OF FUNDS* OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)      ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER: 25,878,893 (1)
		8.	SHARED VOTING POWER:
		9.	SOLE DISPOSITIVE POWER: 25,878,893 (1)
		10.	SHARED DISPOSITIVE POWER:
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 25,878,893 (1)
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*      ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 21.6% (1)(2)
14.	TYPE OF REPORTING PERSON* IN, HC

(1)

Includes 3,125 shares of the common stock of the Issuer underlying options directly held by Julian C. Baker, a principal of the Adviser and 56,000 shares of the common stock of the Issuer underlying options directly held by Dr. Stephen R. Biggar, an employee of the Adviser.

(2)

Based on 119,746,592 shares of the Issuer’s common stock outstanding as of August 10, 2016, as reported in the Issuer’s Prospectus filed with the SEC on August 10, 2016.

CUSIP No.    004225108

Page   5   of   9   Pages

 

1.	NAMES OF REPORTING PERSONS Julian C. Baker
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*      (a) ¨                                                                                                                        (b) ¨
3.	SEC USE ONLY
4.	SOURCE OF FUNDS* OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)      ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER: 25,878,893 (1)
		8.	SHARED VOTING POWER
		9.	SOLE DISPOSITIVE POWER: 25,878,893 (1)
		10.	SHARED DISPOSITIVE POWER:
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 25,878,893 (1)
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*      ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 21.6% (1)(2)
14.	TYPE OF REPORTING PERSON* IN, HC

(1)

Includes 3,125 shares of the common stock of the Issuer underlying options directly held by Julian C. Baker, a principal of the Adviser and 56,000 shares of the common stock of the Issuer underlying options directly held by Dr. Stephen R. Biggar, an employee of the Adviser.

(2)

Based on 119,746,592 shares of the Issuer’s common stock outstanding as of August 10, 2016, as reported in the Issuer’s Prospectus filed with the SEC on August 10, 2016.

Amendment No. 9 to Schedule 13D

 

This Amendment No. 9 to Schedule 13D amends and supplements
the previously filed Schedules 13D filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP), LLC
(the “Adviser GP”), Julian C. Baker and Felix J. Baker. Except as supplemented herein, such statements, as heretofore
amended and supplemented, remain in full force and effect.

The Adviser GP is the sole general partner of the Adviser. Pursuant
to the amended and restated management agreements, among the Adviser, Baker Brothers Life Sciences, L.P. (“Life Sciences”),
14159, L.P. (“14159”), and 667, L.P. (“667”, and together with Life Sciences and 14159, the “Funds”),
and their respective general partners, the Adviser has complete and unlimited discretion and authority with respect to the Funds’
investments and voting power over investments.

Item 3.

Source and Amount of Funds or Other Consideration.

Item 3 of Schedule 13D is supplemented and amended, as the case
may be, as follows:

The disclosure regarding the purchases in Item 4 below is incorporated
herein by reference.

Item 4.

Purpose of the Transaction.

Item 4 of Schedule 13D is supplemented and amended, as the case
may be, as follows:

On August 9, 2016, ACADIA Pharmaceuticals Inc. (“the Issuer”)
entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Goldman, Sachs
& Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the several underwriters listed
on Schedule A thereto (the “Underwriters”), related to a public offering (the “Offering”) of 6,060,606
shares of the Issuer’s common stock at a price to the public of $33.00 per share. In addition, the Issuer granted the Underwriters
an option exercisable for 30 days from the date of the Underwriting Agreement to purchase, at the public offering price less any
underwriting discounts and commissions, up to an additional 909,090 shares of common stock to cover overallotments, if any. The
Offering is expected to close on August 15, 2016.

Pursuant to the Offering, on August 10, 2016, 667 and Life Sciences
purchased 133,153 and 1,169,877 shares of the Issuer’s common stock, respectively, at the offering price of $33.00 per share,
totaling 1,303,030 shares in the aggregate. Each of 667 and Life Sciences purchased the shares of the Issuer’s commons stock
with their working capital.

The Funds hold securities of the Issuer for investment purposes.
The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at
varying times depending upon the Reporting Persons’ continuing assessments of pertinent factors, including the availability
of shares of common stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other
business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions
of the board of directors and management of the Issuer, the availability and nature of opportunities to dispose of shares in the
Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest
with the Issuer, which could include items in subparagraphs (a) through (j) of Schedule 13D.

Depending upon their assessments of the above factors, the Reporting
Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions
to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer, including shares
of common stock (by means of open market purchases, privately negotiated purchases, exercise of some of all of the warrants, exercise
of some or all of the Stock Options, or otherwise) or to dispose of some or all of the securities of the Issuer, including shares
of common stock, under their control.

Except as otherwise disclosed herein, at the present time, the
Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer
including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

 

ITEM 5.

Interest in Securities of the Issuer.

(a) and (b) Items 7 through 11 and 13 of each of the cover pages
of this Amendment No. 9 are incorporated herein by reference.

 

Set forth below is the aggregate number of shares of Common
Stock of the Issuer directly held by each of the Funds, which may be deemed to be indirectly beneficially owned by the Reporting
Persons, as well as shares of Common Stock that may be acquired upon exercise of the 2019 Warrants and the 2018 Warrants (as defined
below) by the Funds, subject to the limitations on exercise described below.

Holder		Shares of Common Stock				2019 Warrants				2018 Warrants
667, L.P.			3,029,953				42,131				–
Baker Brothers Life Sciences, L.P.			22,337,275				447,138				1,426,590
14159, L.P.			452,540				10,731				39,378
Total			25,819,768				500,000				1,465,968

The
warrants to acquire common stock at an exercise price of $0.01 per share with an expiration date of December 17, 2019 (“the
2019 Warrants”) are only exercisable to the extent that after giving
effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), no more than 19.99% of the outstanding shares of Common Stock
of the Issuer. As a result of this restriction, the number of shares that may be issued upon exercise of the 2019 Warrants by the
above holders may change depending upon changes in the outstanding shares of Common Stock.

The
warrants to acquire common stock at an exercise price of $1.38 per share with an expiration date of January 11, 2018 (the
“2018 Warrants”) are only exercisable to the extent that giving
effect to such exercise would not cause the holders thereof and their affiliates to beneficially own, for purposes of Rule 13d-3
under the Exchange Act, in excess of 9.9% of the outstanding shares of Common Stock of the Issuer. As a result of this restriction,
the number of shares that may be issued on exercise of the 2018 Warrants by the above holders may change depending upon changes
in the outstanding shares of Common Stock.

 

The Adviser GP, Felix J. Baker and Julian C. Baker as principals
of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds,
and may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of such securities.

The Reporting Persons disclaim beneficial ownership of the securities
held by each of the Funds, and this Amendment No. 9 shall not be deemed an admission that the Reporting Persons are the beneficial
owners of such securities for purposes of Section 13(d) or for any other purpose.

Julian C. Baker and Stephen R. Biggar currently serve on the
Issuer’s Board of Directors (the “Board”) as representatives of the Funds. The policy of the Funds and the Adviser
does not permit principals or employees of the Adviser to receive compensation for serving as directors of the Issuer, and the
Funds are instead entitled to the pecuniary interest in the options to purchase Common Stock of the Issuer (“Stock Options”).
Julian C. Baker and Dr. Biggar have no voting or dispositive power and no pecuniary interest in the Stock Options previously disclosed
in amendments to this Schedule 13D. Other than through their control of the Adviser, Felix J. Baker and Julian C. Baker have neither
voting nor dispositive power and have no direct pecuniary interest in the Stock Options held by Dr. Biggar.

The Funds are instead entitled to the pecuniary interest in
the Stock Options held by Julian C. Baker and Dr. Biggar previously disclosed in amendments to this Schedule 13D.

Baker Bros. Advisors LP has voting and investment power over
the Stock Options held by Julian C. Baker and Dr. Biggar previously disclosed in amendments to this Schedule 13D.

The Adviser GP, and Felix J. Baker and Julian C. Baker as principals
of the Adviser GP, may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition
of the Stock Options held by Julian C. Baker and Dr. Biggar previously disclosed in amendments to this Schedule 13D.

(c) The disclosure regarding the purchase of common stock of
the Issuer in the Offering described in Item 4 is incorporated by reference herein. Except as described in this Amendment No. 9,
none of the Reporting Persons has effected any transaction in the securities of the Issuer in the past 60 days.

(d) Certain securities of the Issuer are held directly
by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole
general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of
Baker Biotech Capital (GP), LLC.

Certain securities of the Issuer are held directly by Life Sciences,
a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the
sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling
members of Baker Brothers Life Sciences Capital (GP), LLC.

Certain securities of the Issuer are held directly by 14159,
a limited partnership the sole general partner of which is 14159 Capital, L.P., a limited partnership the sole general partner
of which is 14159 Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of 14159 Capital (GP), LLC.

(e) Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true, complete and correct.

August 12, 2016

	BAKER BROS. ADVISORS LP   By: Baker Bros. Advisors (GP) LLC, its general partner
	By:	/s/ Scott L. Lessing
		Name: Scott L. Lessing Title: President

	BAKER BROS. ADVISORS (GP) LLC
	By:	/s/ Scott L. Lessing
		Name: Scott L. Lessing Title: President

	/s/ Julian C. Baker
	Julian C. Baker
	/s/ Felix J. Baker
	Felix J. Baker